Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  linsitinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-301, 2009-012820-97, NCT00924989
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-202, 2009-010319-34, NCT00889382
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-205, 2010-020916-12, NCT01186861
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-207, NCT01221077
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00245, CDR0000724806, MCC-16628, 8873, N01CM00070, N01CM00099, N01CM00100, P30CA076292, NCT01533181
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00247, CDR0000724845, CASE 6810, 8872, U01CA062502, NCT01533246
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00708, CDR0000728619, SARC-022, 8945, NCT01560260
Study of Continuous OSI-906 Dosing
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-101, 2006-005937-39, NCT00514007
Study of Intermittent OSI-906 Dosing
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-102, 2006-005938-20, NCT00514306
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-103, 2008-001743-20, NCT00739453
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GI 124, NCT01154335
A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body
Phase: Phase I
Type: Biomarker/Laboratory analysis
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-906-104, NCT01529684
Start Over